


# GALACTIC-HF TRIAL



AMERICAN COLLEGE of CARDIOLOGY

## Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Randomized, parallel-group, placebo-controlled trial




**Objective:** To evaluate the selective cardiac myosin activator omecamtiv mecarbil compared with placebo among patients with heart failure with reduced ejection fraction (HFrEF) treated with guideline-directed medical therapy.

**8256**  
patients

**Inclusion criteria:** Patients 18-85 years of age with chronic HF symptoms, NYHA class II, III, or IV symptoms, LVEF  $\leq 35\%$ , NT-proBNP  $\geq 400$  pg/ml, BNP  $\geq 125$  pg/ml were included.



**Omecamtiv mecarbil**  
(n = 4,120)



**Placebo**  
(n = 4,112)

### PRIMARY OUTCOME

**37.0**

**Cardiovascular death or HF event %**  
HR 0.92; 95% CI 0.86-0.99; P=0.03

**39.1**

### SECONDARY OUTCOME

**27.7**

**First hospitalization for HF %**  
HR 0.95; 95% CI 0.87-1.03

**28.7**

**19.6**

**Cardiovascular death %**  
HR 1.01; 95% CI 0.92-1.11; 0.86

**19.4**

**Conclusion:** Among patients with HFrEF, those who received omecamtiv mecarbil had a lower incidence of a composite of a HF event or death from cardiovascular causes than those who received placebo.